trending Market Intelligence /marketintelligence/en/news-insights/trending/YfNyG9HkJggQo_xVs5gczA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Albany Molecular Research to be acquired by GTCR, Carlyle Group

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Albany Molecular Research to be acquired by GTCR, Carlyle Group

Private equity firms GTCR LLC and The Carlyle Group LLC are acquiring N.Y.-based Albany Molecular Research Inc. for $21.75 per share in cash.

The cash consideration represents a 42% premium to the 60-day weighted average closing stock price as of April 5, the last trading day prior to public rumors regarding a potential sale process.

The Albany Molecular board has unanimously approved the deal and has recommended shareholders to vote in favor of it. The acquisition is subject to customary closing conditions and is expected to close during the third quarter.

The transaction will be financed through a combination of debt and equity financing.

Credit Suisse Securities (USA) LLC and Goodwin Procter LLP are advising Albany Molecular on the deal.

Latham & Watkins LLP, Barclays and Morgan Stanley & Co. LLC are advising Carlyle. GTCR is being advised by Kirkland & Ellis LLP and RBC Capital Markets LLC.